PMDA announcement on discontinuation of sales of antineoplastic drug tazemetostat hydrobromide
「抗悪性腫瘍剤タゼメトスタット臭化水素酸塩の販売中止について」を掲載しました
Published: 2026-03-27 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-03-27, the Pharmaceuticals and Medical Devices Agency (PMDA) posted an announcement concerning the discontinuation of sales of the antineoplastic drug tazemetostat hydrobromide. The supplied title does not state the reason, timing, or detailed scope of the discontinuation.
Business Impact
Suppliers and healthcare providers handling tazemetostat hydrobromide may face availability implications from the announced sales discontinuation.
Recommended Action
Review of the official Japanese announcement could clarify the discontinuation timing, affected products, and any stated handling arrangements.